95%Confidence
0Views
FDASource
2026-04-16Date
Summary
Redness relief eye drops from K.C. Pharmaceuticals complete the pattern of sterility failures across their entire product portfolio. This affects industrial, pharmacy, and specialty brands, indicating complete breakdown of quality systems.
Actionable: Prepare for potential FDA enforcement actions against K.C. Pharmaceuticals including possible manufacturing suspension.
AI Confidence: 95%
Data Points
firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productSterile EYE DROPS REDNESS LUBRICANT (glycerin 0.25% and naphazoline HCl 0.012%), 0.5 fl oz (15 mL) bottles; a) Industrial Eye Relief, Distributed by:
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now